Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06679634 · ClinicalTrials.gov registry record · Phase 2
Retinoblastoma Phase II Expanded Access Clinical Trial
A Phase 2 study of Retinoblastoma, sponsored by Targeted Therapy Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06679634: Recruiting Phase 2 study of Retinoblastoma, sponsored by Targeted Therapy Technologies.
NCT06679634 is a Phase 2 study of Retinoblastoma that is actively recruiting participants, run by Targeted Therapy Technologies. The registered enrollment target is 30 participants, below the 591-participant average among 15 other Retinoblastoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06679634, a Phase 2 study of Retinoblastoma, is actively recruiting participants, sponsored by Targeted Therapy Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will investigate the utility of a chemoplaque(s) to salvage eyes involved with retinoblastoma. The goal of the study is to further determine/assess the safety and efficacy and optimal chemotherapy dose for retinoblastoma.
Conditions Studied
Interventions
- DRUG Chemoplaque also referred to as Episcleral Topotecan
Study Locations (1)
New York
- NewYork Presbyterian Morgan Stanley Children's Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-21 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
What NCT06679634 shows while recruiting
NCT06679634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 591-participant average among 15 other Retinoblastoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Retinoblastoma appearing as the primary indexed condition, and to 1 intervention - of which Chemoplaque also referred to as Episcleral Topotecan is the first listed.
NCT06679634 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06679634 about?
NCT06679634 is a clinical study titled "Retinoblastoma Phase II Expanded Access Clinical Trial". In this research study investigators want to learn more about treatment of advanced or recurrent retinoblastoma. For children with retinoblastoma that have an advanced stage of presentation in one eye or if they have failed all conventional treatment, eye removal is considered. This study will inves...
What is the current status of trial NCT06679634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-02-21. Estimated completion is 2028-11.
What conditions does trial NCT06679634 study?
This clinical trial studies the following conditions: Retinoblastoma.
What interventions are being tested in trial NCT06679634?
The interventions under investigation include: Chemoplaque also referred to as Episcleral Topotecan (DRUG).
Who is sponsoring clinical trial NCT06679634?
This trial is sponsored by Targeted Therapy Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06679634 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06679634's enrollment target sits among peer trials
30 12th of 15 higher than 3 of 15 other Retinoblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Retinoblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Chemotherapy in Treating Patients With Retinoblastoma
COMPLETED · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
COMPLETED · Phase 2
-
RB Liquid Biopsy Biorepository
RECRUITING
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI